{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:40:59Z","timestamp":1779396059746,"version":"3.53.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002464","name":"Daegu Haany University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002464","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["KK2431-20"],"award-info":[{"award-number":["KK2431-20"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jphs.2025.05.015","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:01:41Z","timestamp":1748635301000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel PDE9 inhibitors, KR39526 and KR39582, attenuate cardiac hypertrophy and fibrosis induced by pressure overload"],"prefix":"10.1016","volume":"158","author":[{"given":"Jeong Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Jo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-0818","authenticated-orcid":false,"given":"Kwang-Seok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2025.05.015_bib1","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.15420\/cfr.2023.05","article-title":"Global public health burden of heart failure: an updated review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card Fail Rev"},{"issue":"10","key":"10.1016\/j.jphs.2025.05.015_bib2","article-title":"Advancements in heart failure management: a comprehensive narrative review of emerging therapies","volume":"15","author":"Sapna","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.jphs.2025.05.015_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/13543784.2024.2349813","article-title":"The role of phosphodiesterase 9A inhibitors in heart failure","volume":"33","author":"Foroshani","year":"2024","journal-title":"Expet Opin Invest Drugs"},{"issue":"25","key":"10.1016\/j.jphs.2025.05.015_bib4","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","article-title":"Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase","volume":"273","author":"Fisher","year":"1998","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.jphs.2025.05.015_bib5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuropharm.2008.07.005","article-title":"The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents","volume":"55","author":"van der Staay","year":"2008","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.jphs.2025.05.015_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.neuropharm.2011.05.009","volume":"61","author":"Hutson","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jphs.2025.05.015_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.biopha.2017.07.084","article-title":"A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases","volume":"94","author":"Shafiee-Nick","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"7544","key":"10.1016\/j.jphs.2025.05.015_bib8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature14332","article-title":"Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease","volume":"519","author":"Lee","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jphs.2025.05.015_bib9","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ehf2.13327","article-title":"Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction","volume":"8","author":"Besler","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"Pt 2","key":"10.1016\/j.jphs.2025.05.015_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1113\/jphysiol.2001.014126","article-title":"Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes","volume":"540","author":"Layland","year":"2002","journal-title":"J Physiol."},{"issue":"25","key":"10.1016\/j.jphs.2025.05.015_bib11","first-page":"2882","article-title":"Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo","volume":"124","author":"Bishu","year":"2011","journal-title":"Circulation (New York, N Y)"},{"issue":"12","key":"10.1016\/j.jphs.2025.05.015_bib12","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jphs.2025.05.015_bib13","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.amjcard.2016.08.077","article-title":"Effect of heart failure with preserved ejection fraction on nitric oxide metabolites","volume":"118","author":"Zamani","year":"2016","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jphs.2025.05.015_bib14","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3390\/ijms23042145","article-title":"Phosphodiesterases and compartmentation of cAMP and cGMP signaling in regulation of cardiac contractility in normal and failing hearts","volume":"23","author":"Calamera","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jphs.2025.05.015_bib15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.RES.0000094745.28948.4D","article-title":"Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A","volume":"93","author":"Kuhn","year":"2003","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.jphs.2025.05.015_bib16","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/aps.2017.38","article-title":"C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling","volume":"38","author":"Wang","year":"2017","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.jphs.2025.05.015_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007300","article-title":"CRD-733, a novel PDE9 (phosphodiesterase 9) inhibitor, reverses pressure overload-induced heart failure","volume":"14","author":"Richards","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jphs.2025.05.015_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jchf.2022.11.006","article-title":"Augmentation of natriuretic peptide bioactivity via combined inhibition of neprilysin and phosphodiesterase-9 in heart failure","volume":"11","author":"Scott","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.jphs.2025.05.015_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2024.2376632","article-title":"The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)","volume":"34","author":"Zhang","year":"2024","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"10.1016\/j.jphs.2025.05.015_bib20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1074\/jbc.271.2.796","article-title":"Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases","volume":"271","author":"Loughney","year":"1996","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.jphs.2025.05.015_bib21","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1074\/jbc.274.20.13729","article-title":"Cyclic GMP phosphodiesterase-5: target of sildenafil","volume":"274","author":"Corbin","year":"1999","journal-title":"J Biol Chem"},{"issue":"26","key":"10.1016\/j.jphs.2025.05.015_bib22","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jphs.2025.05.015_bib23","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","article-title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition","volume":"16","author":"Bischoff","year":"2004","journal-title":"Int J Impot Res"},{"issue":"2","key":"10.1016\/j.jphs.2025.05.015_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1085\/jgp.116.2.147","article-title":"Cyclic nucleotide-gated channels colocalize with adenylyl cyclase in regions of restricted cAMP diffusion","volume":"116","author":"Rich","year":"2000","journal-title":"J Gen Physiol"},{"issue":"9","key":"10.1016\/j.jphs.2025.05.015_bib25","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1177\/0271678X20943823","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"40","author":"Percie du Sert","year":"2020","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.jphs.2025.05.015_bib26","first-page":"1729","article-title":"Transverse aortic constriction in mice","volume":"38","author":"deAlmeida","year":"2010","journal-title":"J Vis Exp"},{"issue":"2","key":"10.1016\/j.jphs.2025.05.015_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.13048\/jkm.16018","article-title":"Cardioprotective effects of salvia miltiorrhiza radix on the pressure overloaded heart failure model by transverse aortic constriction-induced mice","volume":"37","author":"Kim","year":"2016","journal-title":"J Korean Med"},{"issue":"1","key":"10.1016\/j.jphs.2025.05.015_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12012-017-9407-1","article-title":"Protective role of N-acetylcysteine on isoprenaline-induced myocardial injury: histological, immunohistochemical and morphometric study","volume":"18","author":"Zaki","year":"2018","journal-title":"Cardiovasc Toxicol"},{"issue":"5","key":"10.1016\/j.jphs.2025.05.015_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/FJC.0000000000000749","article-title":"cGMP signaling and modulation in heart failure","volume":"75","author":"Blanton","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jphs.2025.05.015_bib30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/978-3-540-68964-5_21","article-title":"Modulation of cGMP in heart failure: a new therapeutic paradigm","volume":"191","author":"Boerrigter","year":"2009","journal-title":"Handb Exp Pharmacol"},{"issue":"4742","key":"10.1016\/j.jphs.2025.05.015_bib31","first-page":"1145","article-title":"Atrial natriuretic peptide elevation in congestive heart failure in the human","volume":"231","author":"Burnett","year":"1986","journal-title":"Sci Technol Humanit"},{"issue":"6","key":"10.1016\/j.jphs.2025.05.015_bib32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1172\/JCI17892","article-title":"Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human","volume":"111","author":"Haghighi","year":"2003","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.jphs.2025.05.015_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hfc.2007.10.007","article-title":"Molecular basis of diastolic dysfunction","volume":"4","author":"Periasamy","year":"2008","journal-title":"Heart Fail Clin"},{"issue":"3","key":"10.1016\/j.jphs.2025.05.015_bib34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.cardiores.2005.08.010","article-title":"Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions","volume":"68","author":"Mattiazzi","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10.1016\/j.jphs.2025.05.015_bib35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrm1151","article-title":"Phospholamban: a crucial regulator of cardiac contractility","volume":"4","author":"MacLennan","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.jphs.2025.05.015_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s004390050838","article-title":"Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence","volume":"103","author":"Guipponi","year":"1998","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/j.jphs.2025.05.015_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11897-012-0109-5","article-title":"Molecular and cellular basis for diastolic dysfunction","volume":"9","author":"van Heerebeek","year":"2012","journal-title":"Curr Heart Fail Rep"},{"issue":"4","key":"10.1016\/j.jphs.2025.05.015_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jphs.2025.05.015_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/00498254.2020.1839982","article-title":"Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy","volume":"51","author":"Grillo","year":"2021","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.jphs.2025.05.015_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1745-7254.2006.00288.x","article-title":"Pharmacokinetics of CPU0213, a novel endothelin receptor antagonist, after intravenous administration in mice","volume":"27","author":"Guan","year":"2006","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"10.1016\/j.jphs.2025.05.015_bib41","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jacbts.2017.07.013","article-title":"Murine models of heart failure with preserved ejection fraction: a \"fishing expedition\"","volume":"2","author":"Valero-Munoz","year":"2017","journal-title":"JACC Basic Transl Sci"},{"issue":"7752","key":"10.1016\/j.jphs.2025.05.015_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132500060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132500060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:48:25Z","timestamp":1750398505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134786132500060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S134786132500060X"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2025.05.015","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel PDE9 inhibitors, KR39526 and KR39582, attenuate cardiac hypertrophy and fibrosis induced by pressure overload","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2025.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}